Imunon, Inc. (LON:0HUZ)
0.8801
-0.0506 (-5.44%)
Jan 29, 2025, 2:56 PM GMT
Imunon Employees
Imunon had 25 employees as of December 31, 2024. The number of employees decreased by 8 or -24.24% compared to the previous year.
Employees
25
Change (1Y)
-8
Growth (1Y)
-24.24%
Revenue / Employee
n/a
Profits / Employee
-426.41K GBP
Market Cap
8.16M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 25 | -8 | -24.24% |
| Dec 31, 2023 | 33 | 2 | 6.45% |
| Dec 31, 2022 | 31 | 2 | 6.90% |
| Dec 31, 2021 | 29 | 2 | 7.41% |
| Dec 31, 2020 | 27 | -2 | -6.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IXICO | 79 |
| Oxford BioDynamics | 41 |
| Fusion Antibodies | 24 |
| Futura Medical | 14 |
| OptiBiotix Health | 10 |
| Theracryf | 9 |
| Genflow Biosciences | 5 |
| Sareum Holdings | 5 |
Imunon News
- 7 days ago - IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY - GlobeNewsWire
- 6 weeks ago - IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 6 weeks ago - IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 - GlobeNewsWire
- 2 months ago - Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study - Slideshow - Seeking Alpha
- 3 months ago - Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and ... - GuruFocus
- 3 months ago - Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Q3 2025 Imunon Inc Earnings Call Transcript - GuruFocus
- 3 months ago - Imunon (IMNN) Q3 2025 Earnings Call Transcript - The Motley Fool